The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Lung Neoplasms

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Lung Neoplasms

  • Possible benefits of vitamin E for prostate cancer prevention and selenium for prostate, colorectal, and lung cancer prevention have emerged only as secondary endpoints in trials conducted for other purposes; confirmatory new trials for these nutrients are now underway or are planned [1].
  • We found that a cohort of patients with lung cancer first treated in 1977 had higher six-month survival rates for the total group and for subgroups in each of the three main TNM stages (tumor, nodes, and metastases) than a cohort treated between 1953 and 1964 at the same institutions [2].
  • We applied this method to the analysis of a model of Kras2-mediated lung cancer and found a good relationship to human lung adenocarcinoma, thereby validating the model [3].
  • These data support an association between low levels of serum vitamin E and the risk of any type of lung cancer and between low levels of serum beta-carotene and the risk of squamous-cell carcinoma of the lung [4].
  • Here, we show that retroviral transfer of the wild-type BRCA1 gene inhibits growth in vitro of all breast and ovarian cancer cell lines tested, but not colon or lung cancer cells or fibroblasts [5].
 

Psychiatry related information on Lung Neoplasms

 

High impact information on Lung Neoplasms

  • Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors [11].
  • The incidence of spontaneous liver and lung cancers was approximately 15 times high in elderly Plk4+/- mice than in Plk4+/+ littermates [12].
  • Furthermore, we found that whereas a gene-expression signature of KRAS2 activation was not identifiable when analyzing human tumors with known KRAS2 mutation status alone, integrating mouse and human data uncovered a gene-expression signature of KRAS2 mutation in human lung cancer [3].
  • Allelic loss at the short arm of chromosome 3 is one of the most common and earliest events in the pathogenesis of lung cancer, and is observed in more than 90% of small-cell lung cancers (SCLCs) and in 50-80% of non-small-cell lung cancers (NSCLCs) [13].
  • CONCLUSIONS: We found no measurable excess risk of death due to lung cancer among women in two chrysotile-asbestos-mining regions [14].
 

Chemical compound and disease context of Lung Neoplasms

  • Treatment of non-small-cell lung cancer with cisplatin and radiotherapy [15].
  • METHODS: We conducted a randomized, double-blind, placebo-controlled dose-escalation study of MGDF in 53 patients with lung cancer who were treated with carboplatin and paclitaxel [16].
  • Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer [4].
  • Uranium mining and lung cancer in Navajo men [17].
  • Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease [18].
  • The result was further confirmed in the animal model, which showed that the A549 lung cancer cells with reduced 14-3-3zeta grew significantly slower than the wild-type A549 cells after cisplatin treatment (P = 0.008) [19].
  • Further, sequence analysis of bisulfite-modified DNA from lung cancer cell lines and from primary lung tumors showed an increased frequency of methylation within the first exon of HtrA3 with a corresponding loss of HtrA3 expression, particularly in tumors from smokers [20].
  • Treatment with the Cdk-2 kinase inhibitor seliciclib reduced lung cancer formation in a murine syngeneic lung cancer model and decreased immunohistochemical detection of the proliferation markers Ki-67 and cyclin D1 in lung dysplasia spontaneously arising in a transgenic cyclin E-driven mouse model [21].
  • These results show in vitro and in vivo that simultaneous inhibition of GSH and Trx metabolism can effectively inhibit lung cancer cell growth and induce chemosensitization by a mechanism that involves thiol-mediated oxidative stress [22].
  • Serial plasma genotyping of EGFR-mutant lung cancer on erlotinib demonstrated pretreatment detection of EGFR mutations, complete plasma response in most cases, and increasing levels of EGFR T790M emerging before objective progression [23].
  • For every 0.1 mg/dL decrease of bilirubin, the risks for lung cancer incidence and mortality increased by 5% and 6% in male smokers, respectively (both P < 0.001) [24].
 

Biological context of Lung Neoplasms

 

Anatomical context of Lung Neoplasms

 

Gene context of Lung Neoplasms

 

Analytical, diagnostic and therapeutic context of Lung Neoplasms

References

  1. What can randomized controlled trials tell us about nutrition and cancer prevention? Byers, T. CA: a cancer journal for clinicians. (1999) [Pubmed]
  2. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. Feinstein, A.R., Sosin, D.M., Wells, C.K. N. Engl. J. Med. (1985) [Pubmed]
  3. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J.J., Ladd-Acosta, C., Mesirov, J., Golub, T.R., Jacks, T. Nat. Genet. (2005) [Pubmed]
  4. Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. Menkes, M.S., Comstock, G.W., Vuilleumier, J.P., Helsing, K.J., Rider, A.A., Brookmeyer, R. N. Engl. J. Med. (1986) [Pubmed]
  5. Growth retardation and tumour inhibition by BRCA1. Holt, J.T., Thompson, M.E., Szabo, C., Robinson-Benion, C., Arteaga, C.L., King, M.C., Jensen, R.A. Nat. Genet. (1996) [Pubmed]
  6. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Antoniades, H.N., Galanopoulos, T., Neville-Golden, J., O'Hara, C.J. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  7. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Ahrendt, S.A., Chow, J.T., Yang, S.C., Wu, L., Zhang, M.J., Jen, J., Sidransky, D. Cancer Res. (2000) [Pubmed]
  8. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. Leighl, N.B., Paz-Ares, L., Douillard, J.Y., Peschel, C., Arnold, A., Depierre, A., Santoro, A., Betticher, D.C., Gatzemeier, U., Jassem, J., Crawford, J., Tu, D., Bezjak, A., Humphrey, J.S., Voi, M., Galbraith, S., Hann, K., Seymour, L., Shepherd, F.A. J. Clin. Oncol. (2005) [Pubmed]
  9. Synthesis and evaluation of nicotine alpha4beta2 receptor radioligand, 5-(3'-18F-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine, in rodents and PET in nonhuman primate. Chattopadhyay, S., Xue, B., Collins, D., Pichika, R., Bagnera, R., Leslie, F.M., Christian, B.T., Shi, B., Narayanan, T.K., Potkin, S.G., Mukherjee, J. J. Nucl. Med. (2005) [Pubmed]
  10. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Loriot, M.A., Rebuissou, S., Oscarson, M., Cenée, S., Miyamoto, M., Ariyoshi, N., Kamataki, T., Hémon, D., Beaune, P., Stücker, I. Pharmacogenetics (2001) [Pubmed]
  11. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Bell, D.W., Gore, I., Okimoto, R.A., Godin-Heymann, N., Sordella, R., Mulloy, R., Sharma, S.V., Brannigan, B.W., Mohapatra, G., Settleman, J., Haber, D.A. Nat. Genet. (2005) [Pubmed]
  12. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Ko, M.A., Rosario, C.O., Hudson, J.W., Kulkarni, S., Pollett, A., Dennis, J.W., Swallow, C.J. Nat. Genet. (2005) [Pubmed]
  13. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Dammann, R., Li, C., Yoon, J.H., Chin, P.L., Bates, S., Pfeifer, G.P. Nat. Genet. (2000) [Pubmed]
  14. Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer. Camus, M., Siemiatycki, J., Meek, B. N. Engl. J. Med. (1998) [Pubmed]
  15. Treatment of non-small-cell lung cancer with cisplatin and radiotherapy. Würschmidt, F., Bünemann, H., Heilmann, H.P. N. Engl. J. Med. (1992) [Pubmed]
  16. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. Fanucchi, M., Glaspy, J., Crawford, J., Garst, J., Figlin, R., Sheridan, W., Menchaca, D., Tomita, D., Ozer, H., Harker, L. N. Engl. J. Med. (1997) [Pubmed]
  17. Uranium mining and lung cancer in Navajo men. Samet, J.M., Kutvirt, D.M., Waxweiler, R.J., Key, C.R. N. Engl. J. Med. (1984) [Pubmed]
  18. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A., Keogh, J.P., Meyskens, F.L., Valanis, B., Williams, J.H., Barnhart, S., Hammar, S. N. Engl. J. Med. (1996) [Pubmed]
  19. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Fan, T., Li, R., Todd, N.W., Qiu, Q., Fang, H.B., Wang, H., Shen, J., Zhao, R.Y., Caraway, N.P., Katz, R.L., Stass, S.A., Jiang, F. Cancer Res. (2007) [Pubmed]
  20. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Beleford, D., Liu, Z., Rattan, R., Quagliuolo, L., Boccellino, M., Baldi, A., Maguire, J., Staub, J., Molina, J., Shridhar, V. Clin. Cancer Res. (2010) [Pubmed]
  21. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Galimberti, F., Thompson, S.L., Liu, X., Li, H., Memoli, V., Green, S.R., DiRenzo, J., Greninger, P., Sharma, S.V., Settleman, J., Compton, D.A., Dmitrovsky, E. Clin. Cancer Res. (2010) [Pubmed]
  22. Enhancement of Carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Fath, M.A., Ahmad, I.M., Smith, C.J., Spence, J., Spitz, D.R. Clin. Cancer Res. (2011) [Pubmed]
  23. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Oxnard, G.R., Paweletz, C.P., Kuang, Y., Mach, S.L., O'Connell, A., Messineo, M.M., Luke, J.J., Butaney, M., Kirschmeier, P., Jackman, D.M., Jänne, P.A. Clin. Cancer Res. (2014) [Pubmed]
  24. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Wen, C.P., Zhang, F., Liang, D., Wen, C., Gu, J., Skinner, H., Chow, W.H., Ye, Y., Pu, X., Hildebrandt, M.A., Huang, M., Chen, C.H., Hsiung, C.A., Tsai, M.K., Tsao, C.K., Lippman, S.M., Wu, X. Clin. Cancer Res. (2015) [Pubmed]
  25. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. Malkin, D., Jolly, K.W., Barbier, N., Look, A.T., Friend, S.H., Gebhardt, M.C., Andersen, T.I., Børresen, A.L., Li, F.P., Garber, J. N. Engl. J. Med. (1992) [Pubmed]
  26. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Chen, H.L., Gabrilovich, D., Tampé, R., Girgis, K.R., Nadaf, S., Carbone, D.P. Nat. Genet. (1996) [Pubmed]
  27. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Kok, K., Osinga, J., Carritt, B., Davis, M.B., van der Hout, A.H., van der Veen, A.Y., Landsvater, R.M., de Leij, L.F., Berendsen, H.H., Postmus, P.E. Nature (1987) [Pubmed]
  28. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. Caraballo, R.S., Giovino, G.A., Pechacek, T.F., Mowery, P.D., Richter, P.A., Strauss, W.J., Sharp, D.J., Eriksen, M.P., Pirkle, J.L., Maurer, K.R. JAMA (1998) [Pubmed]
  29. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Cole, S.P., Bhardwaj, G., Gerlach, J.H., Mackie, J.E., Grant, C.E., Almquist, K.C., Stewart, A.J., Kurz, E.U., Duncan, A.M., Deeley, R.G. Science (1992) [Pubmed]
  30. Inhibition of human leukocyte migration in agar by 3-M potassium chloride extracts of stomach, colon, and lung cancers. Iwaki, J., Akagi, M., Sairenji, T., Hinuma, Y. J. Natl. Cancer Inst. (1979) [Pubmed]
  31. MDR1 gene expression in lung cancer. Lai, S.L., Goldstein, L.J., Gottesman, M.M., Pastan, I., Tsai, C.M., Johnson, B.E., Mulshine, J.L., Ihde, D.C., Kayser, K., Gazdar, A.F. J. Natl. Cancer Inst. (1989) [Pubmed]
  32. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. Arenberg, D.A., Keane, M.P., DiGiovine, B., Kunkel, S.L., Morris, S.B., Xue, Y.Y., Burdick, M.D., Glass, M.C., Iannettoni, M.D., Strieter, R.M. J. Clin. Invest. (1998) [Pubmed]
  33. Cellular retinoic acid-binding protein in human lung carcinomas. Clamon, G.H., Nugent, K.M., Rossi, N.P. J. Natl. Cancer Inst. (1981) [Pubmed]
  34. The FHIT gene 3p14.2 is abnormal in lung cancer. Sozzi, G., Veronese, M.L., Negrini, M., Baffa, R., Cotticelli, M.G., Inoue, H., Tornielli, S., Pilotti, S., De Gregorio, L., Pastorino, U., Pierotti, M.A., Ohta, M., Huebner, K., Croce, C.M. Cell (1996) [Pubmed]
  35. Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Fijneman, R.J., de Vries, S.S., Jansen, R.C., Demant, P. Nat. Genet. (1996) [Pubmed]
  36. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson, D.A., Jacks, T. Nature (2001) [Pubmed]
  37. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Padmanabhan, B., Tong, K.I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.I., Kobayashi, A., Yokoyama, S., Yamamoto, M. Mol. Cell (2006) [Pubmed]
  38. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. Yu, X., Guo, Z.S., Marcu, M.G., Neckers, L., Nguyen, D.M., Chen, G.A., Schrump, D.S. J. Natl. Cancer Inst. (2002) [Pubmed]
  39. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., Volinia, S., Guler, G., Morrison, C.D., Chan, K.K., Marcucci, G., Calin, G.A., Huebner, K., Croce, C.M. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  40. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Konishi, J., Kawaguchi, K.S., Vo, H., Haruki, N., Gonzalez, A., Carbone, D.P., Dang, T.P. Cancer Res. (2007) [Pubmed]
  41. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Engels, E.A., Wu, X., Gu, J., Dong, Q., Liu, J., Spitz, M.R. Cancer Res. (2007) [Pubmed]
  42. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. You, M., Wang, D., Liu, P., Vikis, H., James, M., Lu, Y., Wang, Y., Wang, M., Chen, Q., Jia, D., Liu, Y., Wen, W., Yang, P., Sun, Z., Pinney, S.M., Zheng, W., Shu, X.O., Long, J., Gao, Y.T., Xiang, Y.B., Chow, W.H., Rothman, N., Petersen, G.M., de Andrade, M., Wu, Y., Cunningham, J.M., Wiest, J.S., Fain, P.R., Schwartz, A.G., Girard, L., Gazdar, A., Gaba, C., Rothschild, H., Mandal, D., Coons, T., Lee, J., Kupert, E., Seminara, D., Minna, J., Bailey-Wilson, J.E., Amos, C.I., Anderson, M.W. Clin. Cancer Res. (2009) [Pubmed]
  43. Lung cancer in never smokers: molecular profiles and therapeutic implications. Rudin, C.M., Avila-Tang, E., Harris, C.C., Herman, J.G., Hirsch, F.R., Pao, W., Schwartz, A.G., Vahakangas, K.H., Samet, J.M. Clin. Cancer Res. (2009) [Pubmed]
  44. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Girard, N., Lou, E., Azzoli, C.G., Reddy, R., Robson, M., Harlan, M., Orlow, I., Yatabe, Y., Nafa, K., Ladanyi, M., Viale, A., Kris, M.G., Riely, G., Miller, V., Klein, R.J., Matsuo, K., Pao, W. Clin. Cancer Res. (2010) [Pubmed]
  45. The antioxidant function of the p53 tumor suppressor. Sablina, A.A., Budanov, A.V., Ilyinskaya, G.V., Agapova, L.S., Kravchenko, J.E., Chumakov, P.M. Nat. Med. (2005) [Pubmed]
  46. Improved chemotherapy for small-cell undifferentiated lung cancer. Einhorn, L.H., Fee, W.H., Farber, M.O., Livingston, R.B., Gottlieb, J.A. JAMA (1976) [Pubmed]
  47. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. van Leeuwen, F.E., Klokman, W.J., Stovall, M., Hagenbeek, A., van den Belt-Dusebout, A.W., Noyon, R., Boice, J.D., Burgers, J.M., Somers, R. J. Natl. Cancer Inst. (1995) [Pubmed]
  48. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. Spitz, M.R., Shi, H., Yang, F., Hudmon, K.S., Jiang, H., Chamberlain, R.M., Amos, C.I., Wan, Y., Cinciripini, P., Hong, W.K., Wu, X. J. Natl. Cancer Inst. (1998) [Pubmed]
  49. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. Lippman, S.M., Lee, J.J., Karp, D.D., Vokes, E.E., Benner, S.E., Goodman, G.E., Khuri, F.R., Marks, R., Winn, R.J., Fry, W., Graziano, S.L., Gandara, D.R., Okawara, G., Woodhouse, C.L., Williams, B., Perez, C., Kim, H.W., Lotan, R., Roth, J.A., Hong, W.K. J. Natl. Cancer Inst. (2001) [Pubmed]
 
WikiGenes - Universities